Dr. Raheja has expanded psychiatric care through telepsychiatry, bringing services to rural Wisconsin at Thedacare Regional ...

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with ...

BioXcel Therapeutics (BTAI) provided an update on the progress of its late-stage clinical programs for lead neuroscience asset BXCL501, as well ...

Over the summer, two graduate students attended a highly sought-after training program at Cold Spring Harbor Laboratory (CSHL ...

The main focus in Teva’s innovative portfolio continues to be neuroscience and immunology, with clinical trials for three key assets underway: olanzapine for treatment of schizophrenia, ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...